INTRODUCTION
For patients with high-risk hematological malignancies, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment option. The therapeutic efficacy is based on the emergence of curative immune responses against residual malignant cells in the host induced by donor lymphocytes [1] . Although effective for many patients, undesired immune responses against otherwise healthy tissues frequently occur after HSCT and cause graftversus-host disease (GVHD). Complications related to GVHD are the most important contributors to the high treatment-related morbidity and mortality rates post-HSCT [2] . Therefore, a deeper understanding of the immunological mechanisms that initiate and maintain GVHD is necessary to improve the feasibility and allow broader application of this otherwise elegant immunological treatment approach.
Acute GVHD is primarily caused by donor-derived T cells within the allogeneic stem cell graft that become activated after contact with host-derived antigen-presenting cells (APCs) [3] . These primed allogeneic T cells successively assault healthy tissues (eg, in the liver, gut, and skin), creating GVHD [4] . Although dendritic cells (DCs) are highly potent in T cell priming in general [5] and also important in the context of GVHD, there is considerable debate on the precise role of DCs in the regulation of GVHD. On one hand, host-derived DCs are sufficient for the initiation of GVHD [6] , but on the other, donor-derived DCs may also contribute to the priming of allogeneic T cells [7] . Beyond this, host-derived nonhematopoietic cells may likewise be sufficient to induce GVHD [8, 9] . Interestingly, depletion of specific DC subsets, such as Langerhans cells [10] and conventional or plasmacytoid DC populations, does not prevent GVHD, illustrating the complexity of T cell activation in this setting.
Moreover, DCs are also involved in the maintenance of central and peripheral tolerance [11] , mostly regulated by their activation state [12] and contact with regulatory T (Treg) cells [13] . In particular, CD8a þ DCs are critical for CD8 þ T cell responses initiated by cross-priming [14] but, conversely, may be also involved in the induction of tolerance [15] . With respect to GVHD, vaccination with host-type CD8a þ DCs reduces GVHD [16] , demonstrating the relevance of CD8a þ DCs in the regulation of immune responses after HSCT. Moreover, CD8a þ DCs play a role for the induction of graft-versus-tumor (GVT) responses, as shown in a minor histocompatibility antigen (miHA) mismatched HSCT model [2, 17] . Nevertheless, the direct role of CD8a þ DC in induction of GVHD has only been incompletely defined.
To elucidate the role of host-derived DCs in the initiation of GVHD, we used 2 transgenic mouse strains deficient of CD11c þ DC populations in a mouse model of acute GVHD and surprisingly found a strong increase in GVHD-related mortality in the absence of CD11c þ cells. Because Batf3-deficient 
METHODS

Reagents
Anti-NK1.1 mAb (clone PK136) was purified from hybridoma supernatants according to standard protocols. If required, mAbs were affinity purified using protein G-Sepharose columns (GE Healthcare, Munich, Germany).
Mice
C57BL/6 (B6) and BALB/c were obtained from Charles River Laboratories (Sulzfeld, Germany). Batf3 deficient (B6.129S(C)-Batf3 tm1.1Kmm /J; Batf3 -/-) mice were from The Jackson Laboratory (Sulzfeld, Germany). Batf3 -/-mice were backcrossed for 10 generations with B6 and at least 1 filial generation upon purchase. Filial breedings were continued at our center. All mice were bred in a specific pathogen-free colony in the animal facility of the Johannes Gutenberg-University. CD11c-Cre [19] , DTA [20] , and inducible diphtheria toxin receptor (iDTR) [21] mice were from A. Waisman (Mainz) and bred as previously described [22] . All animal procedures were performed in accordance with the institutional guidelines and approved by the responsible national authority (National Investigation Office Rheinland-Pfalz, approval ID AZ 23 177-07/G11-1-034).
Bone Marrow Transplantation Model and Histopathology Scoring
Mice were transplanted following a standard protocol as previously described [23] . B6 recipients were natural killer cell depleted with an anti-NK1.1 specific antibody (clone PK136, 500 mg i.p. per mouse on day À2) and received allogeneic T celledepleted bone marrow cells (10 7 Cs source (OB58-BA, Buchler, Braunschweig, Germany). The animals were maintained under specific pathogen-free conditions and received antibiotics (sulfadoxine-trimethoprim 1 g/mL in drinking water) posttransplantation. For in vivo DC depletion, CD11c-iDTR mice were injected i.p. with 25 ng/g body weight diphtheria toxin (Sigma-Aldrich, Taufkirchen, Germany) on days À2 and 1.
Clinical symptoms of GVHD were monitored daily by assessing weight loss, posture, activity, fur texture, and skin integrity, adding up to a clinical GVHD score as previously described [24] . Animals with severe GVHD defined by clinical scores !6 were killed as required by the institutional animal ethics guidelines and the day subsequent to death determined as the following day.
Samples of large intestine, liver, and skin were taken on day 10 and stained with H & E. The sections were reviewed and scored by one of the authors (B.R.) who was blinded to the experimental groups according to a previously published histopathology scoring system [11, 25] .
Flow Cytometry Staining and Analyses
All analyses were performed with an LSRII flow cytometer and FACSDiva (Becton Dickinson, Heidelberg, Germany) or FlowJo (Tree Star Inc, Ashland, OR, USA) software. The following mAbs were used: CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD11c (clone N418), MHC class II (clone M5/114.15.2), CD45.2 (clone 104), CD80 (clone 16-10A1), CD86 (clone GL1), CD90.2 (clone 53-2.1), CD229.1 (clone 30C7), PD-L1 (clone 10F.9G2), PD-L2 (clone 122), and FoxP3 (clone FJK-16S) (all antibodies were purchased from Biolegend, San Diego, CA, USA or eBioscience, Frankfurt, Germany). Viability was determined by propidium iodide (Sigma-Aldrich). Total cell counts in the spleen were determined by flow cytometry using counting beads (Beckmann-Coulter, Krefeld, Germany) according to the manufacturer's instructions.
Cell Purification and Culture
Splenic DCs were purified by digestion using DNase I (100 mg/mL; Sigma-Aldrich) and collagenase type 2 (1 mg/mL; Worthington Biochemical Corporation, Lakewood, NJ, USA) followed by density centrifugation as described previously [12, 23] and further enriched by using CD11c specific magnetic microbeads according to the manufacturer's protocol (Miltenyi Biotech, Bergisch Gladbach, Germany). These cells were typically >95% CD11c þ as determined by flow cytometry. 
Detection of IL-2 and TGF-b
Mice were killed on day 7 post-HSCT by CO 2 asphyxiation and peripheral blood taken by retro-orbital bleeding and centrifuged. Cell free serum samples were frozen at À20 C until required. IL-2 was detected by a specific ELISA using anti-mIL-2 (JES6-1A12) and biotinylated anti-mIL-2 (JES6-5H4; both from BD Biosciences, Heidelberg, Germany) as previously described [26] . TGF-b ELISA (from R&D Systems, Wiesbaden, Germany) was used according to the manufacturer's instructions.
Statistical Analysis
Analyses were performed by a 2-tailed Student's t-test for comparison between 2 groups as indicated. Multiple groups were compared by 1-way ANOVA with Bonferroni's post-test. Survival analysis was performed by the Mantel-Cox test. For all analyses, P < .05 was considered significant. All statistical analyses were performed using GraphPad Prism (version 5.0a for Mac OS X, GraphPad Software, San Diego, CA, USA, www.graphpad.com).
RESULTS
Host-Derived Conventional DCs Are Dispensable for the Induction of Acute GVHD
To analyze the general role of conventional DCs in GVHD induction, we used our previously described diphtheria toxin A (Rosa-DTA) model [22] in which DCs are continuously ablated when crossed to the CD11c-Cre line 21. We used a well-established mouse model for HSCT, where C57BL/6 (B6) or DC-deficient CD11c-DTA recipients received a lethal dose of TBI (11 Gy) and were transplanted with T celledepleted bone marrow and purified T cells from MHC and miHA mismatched BALB/c donors. Wild-type B6 animals developed clinical signs of acute GVHD as evidenced by weight loss, decreased activity, and loss of fur (not shown), resulting in a lethal course of disease in all animals with a median survival of 28 days ( Figure 1A ). Unexpectedly, DC-deficient CD11c-DTA mice developed more severe signs of GVHD as compared with controls, resulting in death of all transplanted CD11c-DTA recipients within a significantly accelerated timeframe (median survival of 11 days, P < .001 by Mantel Cox test).
Because the continuous ablation of DCs resulted in an autoimmune disorder phenotype because of the lack of control by Treg cells [27] , we next used another model of transient DC ablation in vivo. For this we used our previously described iDTR model crossed to the CD11c-Cre line (CD11c-iDTR) [22] . Depletion of DCs in these mice was achieved by the injection of diphtheria toxin. As shown in Figure 1B , when transplanting CD11c-iDTR recipients with or without additional DC depletion by diphtheria toxin treatment, we observed all mice that had received diphtheria toxin rapidly died (median survival, 8 days), similar to the course of GVHD in CD11c-DTA mice ( Figure 1A ). In contrast, CD11c-iDTR recipients not receiving diphtheria toxin displayed a prolonged survival (median survival, 23 days, P < .001 by Mantel Cox test), comparable with the course of GVHD in B6 recipients.
DCs are a heterogeneous population of cells, and distinct DC subsets may exert diverse effects on the immune responses post-HSCT. Therefore, we decided to focus on 1 particular subset, namely CD8a þ DCs, that are a defined lineage depending on the AP1 transcription factor Batf3. Hence, Batf3 -/-mice constitutively lack the CD8a þ DC subpopulation [14] . As depicted in Figure 1C , the transplanted wild-type B6 animals developed acute signs of illness, and nearly all mice succumbed to GVHD (94%; median survival, 43 days), whereas Batf3 -/-mice displayed a strongly aggravated course of GVHD as illustrated by the 100% lethal outcome and a median survival of 8 days (P < .001 by Mantel Cox test). When comparing transplanted wild-type B6 and Batf3 -/-mice for histological evidence of GVHD ( Figure 1D ), we detected increased signs of GVHD in the colon (P < .05 by Student's t-test) and in the liver, the latter not reaching statistical significance (P ¼ .15 by Student's t-test). In contrast, we found decreased signs of GVHD in the skin as another typical GVHD target organ (P < .05 by Student's t-test), suggesting a distinct role of CD8a þ DCs during GVHD in different target organs. Taken together, these results indicate in 3 distinct models that host-derived conventional DCs are protective against the adverse outcomes. Apparently, the organ-specific distribution of DC subsets contributes to the pace and histopathology phenotype of GVHD.
Rapid Depletion and Concurrent Activation of Host DCs after HSCT
Allogeneic T cell priming occurs on contact of transplanted donor T cells with host APCs [28] . Because hostderived DCs were not required for the induction of GVHD and the TBI conditioning regimen rapidly depletes various hematopoietic cell types, inducing apoptosis, including DCs [29] , we were interested in the depletion kinetics of To further investigate whether the DCs shown in Figure 2A were of host or donor origin, we used the congenic surface marker CD229.1 (Ly9.1) expressed only in hematopoietic cells from BALB mice [31] and assessed the DC chimerism in the spleen over time by flow cytometry. Most DCs were of host origin until day 3 post-HSCT ( Figure 2D ). Although the absolute numbers of DCs were very low by day 4, it appears possible and consistent with previous data [30] that a sufficient number of host-or donor-derived DCs are present during the initial phase of GVHD to influence the course of GVHD.
CD8a
þ DCs Suppress the TBI-Induced Activation of the
Remaining DC Subsets
Because we observed an aggravated course of GVHD in the absence of host conventional DCs and conversely in the absence of CD8a þ DCs, we were interested in the activation phenotype of CD8a þ versus CD8a À DC subsets after HSCT. Figure 4A using MLN cells from untreated mice as stimulators, we only observed a minor increase in T cell proliferation in the presence of Batf3 -/-cells compared with the wild-type B6 controls (P < .05 by paired Student's t-test). In contrast, when using MLN cells from mice 24 hours post-TBI conditioning as stimulators, we observed a reduction of T cell proliferation by about 50% compared to the wild-type B6 controls ( Figure 4B ), most likely due to a TBI-induced reduction of APC numbers. On the other hand, we detected a strongly enhanced T cell response induced by Batf3 -/-MLN cells after TBI. Thus, the absence of CD8a þ DCs not only leads to a more activated DC phenotype after TBI but also induces an enhanced allogeneic T cell response compatible with the aggravated course of GVHD and increased GVHD-related mortality observed in Batf3 -/-mice upon HSCT. 
DISCUSSION
Although nonhematopoietic cells can induce GVHD [8] , host-derived hematopoietic APCs have been shown to be the essential for the induction of GVHD [3, 34] . Although hostderived DCs are sufficient to mediate GHVD [6] , we used 2 models of conventional DC depletion to clearly show that host-derived CD11c þ DCs are not necessary, which is well in line with a previous report by Li et al. [11] . Although they had to use bone marrow chimeras of CD11c-DTR mice for HSCT [35] because repeated diphtheria toxin treatments are lethal in these animals due to promiscuous expression of the transgene [36] , this problem does not occur in the CD11c-iDTR strain we used [22] . Therefore, our results are important because they add a distinct model system (CD11c-iDTR strain) and independently confirm the previous data [11] . From our own previous work, where we have extensively characterized the residual DCs in the CD11c-iDTR and CD11c-DTA strains, we know that less than 5% of the normal DC numbers are left in the host [22] . Therefore, we cannot formally exclude that these remaining DCs are sufficient to induce GVHD. However, this degree of DC depletion is sufficient to ablate immune responses in other models [21, 35, 37] . Although it remains controversial to what extent DCs are required for the induction of GVHD, our results allow the conclusion that host-derived DCs contribute to the amelioration of GVHD, raising the question what DC subpopulation is involved. Toubai et al. [16] previously demonstrated that the vaccination with host-type CD8a þ DCs suppresses GVHD.
Hence, a suppressive effect of this DC subset on the course of GVHD can be anticipated. Consistent with this notion, we observed an aggravated course of GVHD in Batf3 -/-mice where CD8a þ DCs are lacking because the development of CD8a þ DCs depends on the AP1 transcription factor Batf3 [14] . Our results nicely complement previous observations by Teshima [38] detecting an expansion of CD8a þ DCs and a decrease of GVHD-related mortality upon treatment of the HSCT recipient with Flt3 ligand. The augmented GVHDrelated mortality in Batf3 -/-mice and the enhanced MLR using Batf3 -/-APCs as stimulators are also compatible with an enhanced allogeneic T cell priming induced by more activated residual DCs in the absence of CD8a þ DCs [39] . This supports our ex vivo data showing increased levels of Ifng mRNA in the DCs from the MLNs on day 2 and increased IL-2 levels in the serum on day 7 post-HSCT in Batf3 -/-recipients compared with the wild-type controls. Notably, we were unable to detect any significant differences in the recovery of donor T cells or CD4/CD8 ratios post-HSCT of Batf3 -/-or wildtype recipients ( Figure 5A ). However, this may still be compatible with the enhanced activation of allogeneic T cells in Batf3 -/-recipients because most effector cells may have been recruited to GVHD target organs (ie, gut and liver) as suggested by our histopathology findings ( Figure 1D ). Interestingly, we found significantly increased histopathology signs of GVHD in the gut as opposed to the skin where the signs of GVHD were diminished. Although we did not follow up on this observation, this can be suspected to be related to differences in the distribution of CD8a þ DCs and the related nonlymphoid CD103 þ DCs in the intestine versus the skin [40, 41] . As shown in Figure 2 , host DCs were rapidly depleted after TBI, leaving only a narrow time frame of 3 to 4 days for priming of allogeneic T cells, which is in line with previous reports [13, 30] [18] . This is mediated by compensatory mechanisms via Batf. Therefore, it needs to be considered for our data that CD8a þ DCs may be induced in Batf3 -/-hosts upon TBI that we were unable to detect. However, given the rapid depletion of host DCs after lethal TBI ( Figure 2 ) and the enhanced GVHDrelated mortality in Batf3 -/-hosts (Figure 1 ), these Batfdependent mechanisms are apparently insufficient to fully compensate the primary lack of CD8a þ DCs in Batf3 -/-hosts.
Therefore, our results allow the conclusion that host CD8a þ DCs are important counter-regulators in the initiation phase of GVHD. In contrast to our results, a study using a murine miHA mismatch model showed no role for Batf3-dependent CD8a þ DCs in GVHD induction but a requirement of this cell population to induce an optimal GVT reaction [17] . However, an obvious difference to our study is the MHC-matched HSCT model and the use of purified CD8 þ T cells in the graft, where the ability of CD8a þ DC for the cross-presentation of tumorrelated miHA is clearly important. It appears unlikely that a lack of cross-presentation of miHA can explain this difference, because miHA are ubiquitously and directly presented by all host APCs in contrast to tumor antigens for the GVT effect, which have to be taken up and presented by host APCs. However, another major difference between both models is that GVHD in the C3H.SW/B6 model is more CD8 þ T cell dependent, whereas our BALB/c/B6 model mainly requires CD4 þ T cells and CD8 þ T cells to a lesser extent [42] . Nevertheless, in the model of Toubai et al. [17] no CD4 þ T cells were transplanted, which may contribute to the severity and kinetic of GVHD and explain the differences in outcome. However, when considering the role of CD8a þ DCs for GVT-specific CTL responses [17] in context of our results demonstrating suppressive effects on priming of GVHspecific T cell responses, it is tempting to speculate that targeting of CD8a þ DCs may be important gate keepers to separate GVH from GVT responses to concurrently improve the efficacy (GVT) and reduce toxicity (GVH) of HSCT. Although clinical evidence in humans is currently missing, the previous work by Teshima [38] using FLT3 ligand to expand CD8a þ DCs in a similar MHC mismatched model of GVHD (B6/B6D2F1) suggests a potential way to go. The importance of the interaction of APCs with CD4 þ T cells is not only evident for priming of T cell responses in the context of GVHD but also for the induction or maintenance of tolerance, as Treg cells are of well-known significance in controlling GVHD by various mechanisms [23, 43, 44] . In this instance, it is interesting to note that CD8a þ DCs can induce Treg cells in a TGF-b dependent fashion [32, 45] . Conversely, Treg cells preferentially make contact with DCs inhibiting their activation, as previously shown by us and others [46, 47] . We detected a hyperactivated DC phenotype after the TBI conditioning regimen along with an enhanced MLR response in the absence of CD8a þ DCs ( Figure 4B ). Because of the low recovery of DCs from the MLNs post-TBI, we unable to directly perform the MLRs with ex vivo purified DCs. Therefore, our experimental setup does not allow to discriminate whether the enhanced alloreactivity is mediated by CD8a þ DCs in a direct or indirect fashion.
The enhanced DC and T cell activation in Batf3 -/-hosts was accompanied by a reduced number of Treg cells and decreased TGF-b levels post-HSCT, suggesting the aggravated course of GVHD observed in Batf3 -/-mice is related by a diminished induction of Treg cellemediated tolerance leading to enhanced T cell priming and the exacerbation of GVHD, although we did not provide a direct evidence for this in our study. However, a similar mechanism involving Batf3-dependent DCs mediated via PD-1 is in place for tolerance induction in the kidney [48] . Likewise, PD-1 is necessary for the DC-mediated induction of Treg cells in a model of experimental autoimmune encephalitis [22] . Although the PD-1/PD-L1 interaction in general is also highly important for GVHD [49] , we detected an increased expression of PD-L1 and PD-L2 on DCs from wild-type as well as Batf3 -/-mice post-TBI, suggesting these inhibitory B7 molecules are not the key regulators of allogeneic T cell priming in this context. Taken together, we confirmed that conventional DCs are not required for the induction of acute GVHD but also demonstrated an important role of host-derived CD8a þ DCs in counter-regulating the early inflammatory response after HSCT. This is relevant for the severity and mortality of acute GVHD. Our results enhance our current understanding of how GVHD is initiated and may provide the basis for novel concepts for an improved control of GVHD and better feasibility of HSCT in the future.
